Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640205 | 1.00 | LMNA (0.32) | LMNACYP2C9GBA1CHRM2CHRM1 | |
| SCHEMBL12217040 | 0.90 | LMNA (0.33) | LMNACYP2C9GBA1CHRM2CHRM1 | |
| SCHEMBL30203 | 0.81 | CYP2C9 (0.32) | CYP2C9GBA1 | |
| SCHEMBL13900980 | 0.81 | CYP2C9 (0.32) | CYP2C9GBA1 | |
| SCHEMBL14473283 | 0.81 | CYP2C9 (0.32) | CYP2C9GBA1 | |
| SCHEMBL16800305 | 0.80 | GBA1 (0.33) | GBA1 | |
| SCHEMBL172113 | 0.79 | GBA1 (0.30) | GBA1 | |
| SCHEMBL3104581 | 0.79 | GBA1 (0.30) | GBA1 | |
| SCHEMBL10035795 | 0.77 | FUCA1 (0.33) | — | |
| SCHEMBL8863482 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11788009-B2 | Liquid-crystalline medium for use in a switching element | MERCK PATENT GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11667845-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3848436-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20210171830-A1 | LIQUID-CRYSTALLINE MEDIUM FOR USE IN A SWITCHING ELEMENT | MERCK PATENT GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| US-10975308-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| US-10738243-B2 | Liquid-crystalline medium and liquid-crystal display | MERCK PATENT GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3666853-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181493-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| EP-3487955-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3368637-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-1832643-A1 | Liquid crystalline medium and liquid-crystal display | Merck Patent GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1808473-A1 | Liquid crystal medium | Merck Patent GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1310542-B1 | Liquid crystalline compound, medium and display | MERCK PATENT GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1570025-B1 | LIQUID CRYSTAL COMPOSITION FOR USE IN BISTABLE LIQUID CRYSTAL DEVICES | MERCK PATENT GMBH (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-7201951-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2007-04-10 | — | — | US | disclosed |
| WO-2007017008-A1 | ELECTRO-OPTICAL LIGHT MODULATION ELEMENT, DISPLAY AND MEDIUM | MERCK PATENT GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1431369-B1 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2007009636-A1 | S-INDACENE AND INDENO[5,6-D][1,3]DIOXOL-DERIVATIVES AND USE THEREOF AS COMPONENTS OF LIQUID-CRYSTAL MIXTURES | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070001149-A1 | Liquid-crystal medium containing monofluoroterphenyl compounds | MERCK PATENT GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| EP-1365001-B1 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667845-B2 | Liquid crystalline medium | NEFM, CCNI, MYT1 | LMNA 885/4885CYP2C9 887/4885GBA1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.